Skip to content

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01089283
Enrollment
80
Registered
2010-03-18
Start date
2010-03-31
Completion date
Unknown
Last updated
2010-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

parkinson, fdg pet-ct, i123 dat scan, LRRK2, GBA, parkinson patients with known genetic characteristic

Brief summary

Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation. Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group. The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute. The examination results will be given to the participants by a doctor from the neurology department.

Interventions

None listed

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnosed Parkinson patients with known genetic characteristics

Exclusion criteria

* patients unable to understand and sign an informed consent * minors * patients in medical condition that does not allow them to stay still during the examination

Countries

Israel

Contacts

Primary ContactEinat Even-sapir, PhD, MD
evensap@tasmc.health.gov.il972-3-6974444
Backup ContactAyelet Kurzband, BA
ayeletk@tasmc.health.gov.il972-3-6974444

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026